Home > Healthcare > Pharmaceuticals > Vaccines > Rabies Vaccine Market

Rabies Vaccine Market Trends

Report ID: GMI9865
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Rabies Vaccine Market Trends

The increasing incidence of rabies is a significant driver of the market. Despite being preventable, rabies remains a major public health concern in many parts of the world, particularly in Asia and Africa, where access to preventive healthcare and vaccination is limited.
For instance, as per the WHO, rabies is estimated to cause 59,000 human deaths annually in over 150 countries, with 95% of cases occurring in Africa and Asia.
This rising number of reported rabies cases, coupled with increased awareness of the disease's fatal nature, has led to a growing demand for effective vaccination programs.
Moreover, governments and health organizations are intensifying efforts to control rabies through mass vaccination campaigns for both humans and animals, further propelling the market for rabies vaccines.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global rabies vaccine industry was valued at USD 1.1 billion in 2023 and is anticipated to register 4.5% CAGR between 2024 and 2032, driven by increasing incidence of rabies and technological advancements in vaccine production.

The human segment in the market is expected to reach USD 418.51 million by 2032 due to the increasing incidence of rabies and heightened awareness about the fatal consequences of rabies.

North America rabies vaccine market is expected to reach USD 635.7 million by 2032 due to the region's robust healthcare infrastructure and high awareness of rabies prevention.

Bavarian Nordic A/S, Bharat Biotech International Limited, Bio-Manguinhos/Fiocruz, Cadila Pharmaceuticals, China National Biotec Group Co., Elanco Animal Health Incorporated, GSK plc., and Indian Immunologicals Ltd., among others.